Faron Pharmaceuticals Reports 43% Complete Remission Rate in High-Risk Myelodysplastic Syndrome Trial
核心洞察
Faron Pharmaceuticals (搜索)' BEXMAB study showed 43% of newly diagnosed high-risk myelodysplastic syndrome patients achieved complete remission with bexmarilimab plus azacitidine combination therapy.
The complete remission rate increased from 28% in earlier trial results, significantly outperforming standard azacitidine monotherapy's historical 16-17% remission rate.
The company is preparing for an end-of-phase II FDA meeting to advance bexmarilimab toward a pivotal registrational trial for accelerated approval.
Faron Pharmaceuticals (搜索) Limited reported encouraging results from its ongoing BEXMAB study, showing that 43% of newly diagnosed high-risk myelodysplastic syndrome (HR-MDS) patients achieved complete remission when treated with the combination of bexmarilimab and azacitidine chemotherapy. The complete remission rate represents a notable improvement from the 28% rate observed in earlier trial results.
Improved Efficacy Over Standard Care
The latest data demonstrates significant advantages over standard treatment approaches. Complete remission, defined as the restoration of normal blood and bone marrow function, serves as the gold standard for evaluating treatment success in this aggressive form of blood cancer. In comparison, standard azacitidine therapy alone has historically achieved remission rates of just 16-17%.
The updated readout is being prepared for an upcoming end-of-phase II meeting with the US Food and Drug Administration, representing a crucial step toward advancing bexmarilimab into a pivotal registrational trial.
Deepening Treatment Responses
The new results indicate that many patients previously categorized as partial responders are now progressing to full remission. Faron also reaffirmed its earlier composite complete remission (cCR) rate of 50%, a broader measure that includes both complete and near-complete responses.
"This deepening of responses is very encouraging," said Petri Bono, Faron's chief medical officer. "It gives us two compelling and clinically meaningful data sets for our discussions with the FDA."
Path to Regulatory Approval
The company now aims to advance toward a registrational trial that could support accelerated approval for bexmarilimab in HR-MDS. The improved efficacy data positions the experimental drug as a potential significant advancement in treating this challenging hematologic malignancy.
The positive trial results drove Faron's share price up 19%, with shares rising 37p to 232p following the announcement.